Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial
Precision BioSciences (NASDAQ:DTIL) has announced it has dosed the first patient in its Phase 1/2 a clinical trial of PBCAR0191,...
Myriad Genetics Submits First Module of Premarket Approval Application to FDA for myChoice® HRD CDx Test
Myriad Genetics (NASDAQ:MYGN) has announced it has submitted the first module of its premarket approval (PMA) application to the US...
TetraGenetics and ImmunoPrecise Extend Collaboration With Multi-Target Service Agreement
ImmunoPrecise Antibodies (TSXV:IPA, OTC Pink:IPATF) has announced it has extended its collaboration with TetraGenetics. As quoted in the press release:...
Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options
Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated...
Applied Genetic Technologies Announces Enrollments in Phase 1/2 Clinical Trials
Applied Genetic Technologies (NASDAQ:AGTC) has announced it has reached two milestones in two of its Phase 1/2 clinical trials. As...
NewLink Genetics Presents Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
NewLink Genetics (NASDAQ:NLNK) has announced results from its Phase 2 study of NLG207, a nanoparticle of the topoisomerase 1 inhibitor...
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility
bluebird bio (NASDAQ:BLUE) has announced the opening of its first wholly owned manufacturing facility in Durham, North Carolina, which will...